Researchers have shown the anti-sense inhibitors, that target PLK1 inducing a synergistic effect of taxane and paclitaxel, thereby enhancing the sensitivity of breast cancer cells to these drugs in vivo and in vitro [26]. Here, PLK1 is linked to breast carcinoma.